Literature DB >> 31748801

Discontinuing febuxostat might cause more deaths than continuing febuxostat: the untold story from the CARES trial.

Byeongzu Ghang1,2, Soo Min Ahn1, Jinseok Kim2, Yong-Gil Kim1, Chang-Keun Lee1, Bin Yoo1.   

Abstract

Entities:  

Year:  2020        PMID： 31748801     DOI： 10.1093/rheumatology/kez552

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  1 in total

1.  Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial.

Authors:  Byeong-Zu Ghang; Ji Sung Lee; Jihye Choi; Jinseok Kim; Bin Yoo
Journal:  RMD Open       Date:  2022-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.